
Retatrutida, also known as LY3437943, is designed to act on three incretin/metabolic signaling pathways: GLP-1 receptor activity, GIP receptor activity, and glucagon receptor activity. This distinguishes it from semaglutide, which targets GLP-1, and from tirzepatide, which targets GIP and GLP-1. The triple agonist framework is designed to influence appetite regulation, glucose management, insulin-related signaling, and energy expenditure biology.


Videos by independent creators on YouTube. BioVantix doesn't make or endorse them, and they aren't usage instructions. They load from YouTube only when you play them.